FDA Approves Poteligeo for Rare Types of Non-Hodgkin LymphomaThe U.S. Food and Drug Administration (FDA) has approved Poteligeo (mogamulizumab-kpkc), a targeted treatment for people with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), who have previously... By Editorial Team3 min readBookmark for later Reactions 0 reactions Comments0 comments
First Targeted Treatment for Relapsed or Refractory AML with IDH1 MutationThe U.S. Food and Drug Administration (FDA) has approved the first targeted treatment for people with acute myeloid leukemia (AML) that has relapsed or is refractory (hasn’t responded to previous... By Editorial Team2 min readBookmark for later Reactions 0 reactions Comments0 comments
Take the Impact of Cancer Survey!Managing life with cancer can be incredibly difficult. While some treatments and side effects have become common knowledge, there is so much more about life after a cancer diagnosis that... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Keytruda for Refractory or Relapsed Primary Mediastinal Large B-Cell LymphomaThe U.S. Food and Drug Administration (FDA) has recently given accelerated approval for Keytruda® (pembrolizumab) to treat adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL) or... By Pamela Munnelly1 min readBookmark for later Reactions 0 reactions Comments0 comments
FDA Expands Venclexta Approval for Broader Treatment of CLL and SLLThe U.S. Food and Drug Administration (FDA) has recently expanded the approval for Venclexta® (venetoclax). Venclexta is now approved to treat chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)... By Emily Downward2 min readBookmark for later Reactions 0 reactions Comments0 comments
Take the Clinical Trial Patient Experience Survey!Have you participated in a clinical trial? We want to hear more about your experience! We are conducting a short survey to understand how patients are involved in the clinical... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments0 comments
Expanded Approval for Darzalex – Newly Diagnosed, Transplant-Ineligible Multiple MyelomaThe U.S. Food and Drug Administration (FDA) has recently expanded the usage of Darzalex® (daratumumab): it is now approved to be used in combination with Velcade® (bortezomib), melphalan, and prednisone... By Emily Downward2 min readBookmark for later Reactions 0 reactions Comments0 comments
CAR T-Cell Therapy Kymriah Now Approved for Adult Diffuse Large B-Cell LymphomaThe U.S. Food and Drug Administration (FDA) recently expanded the approval of Kymriah™ (tisagenlecleucel) to include adults with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma... By Emily Downward3 min readBookmark for later Reactions 0 reactions Comments0 comments
Newly Approved Front-Line cHL Treatment Was First in Over 40 YearsRecently, the United States Food and Drug Administration (FDA) announced the approval of a new front-line treatment combining Adcetris® (brentuximab vedotin) and chemotherapy for stage III or IV classical Hodgkin... By Editorial Team2 min readBookmark for later Reactions 0 reactions Comments0 comments
